NCT06760208 A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
| NCT ID | NCT06760208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pfizer |
| Condition | Pneumococcal Immunization |
| Study Type | OBSERVATIONAL |
| Enrollment | 660 participants |
| Start Date | 2025-11-13 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 660 participants in total. It began in 2025-11-13 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea. This study is seeking for participants who are: * Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older * Prescribed Prevenar 20 by their physician as per approved product label All participants in this study will receive Prevenar 20 vaccine. 1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle. We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe. Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.
Eligibility Criteria
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older 2. Subjects who have been prescribed Prevenar 20 by their physician as per approved product label 3. Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study Exclusion Criteria: Subjects meeting any of the following criteria will not be included in the study: 1. Subjects with contraindication according to approved label of Prevernar 20 (Pneumococcal 20-valent conjugate vaccine) 2. Any subjects (or a legally acceptable representative) who do not agree that Pfizer and companies working with Pfizer use his/her information
Contact & Investigator
Pfizer CT.gov Call Center
STUDY DIRECTOR
Pfizer
Frequently Asked Questions
Who can join the NCT06760208 clinical trial?
This trial is open to participants of all sexes, aged 6 Weeks or older, studying Pneumococcal Immunization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06760208 currently recruiting?
Yes, NCT06760208 is actively recruiting participants. Contact the research team at ClinicalTrials.gov_Inquiries@pfizer.com for enrollment information.
Where is the NCT06760208 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06760208 clinical trial?
NCT06760208 is sponsored by Pfizer. The principal investigator is Pfizer CT.gov Call Center at Pfizer. The trial plans to enroll 660 participants.